Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
Malnick
Stephen D H
SD
Basevitch
Alon
A
D000208:Acute Disease; D000998:Antiviral Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012189:Retrospective Studies; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b